Lenvatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lenvatinib: From Thyroid Cancer / Renal Cell Carcinoma to Liposarcoma
One-Sentence Summary
Lenvatinib is a multi-kinase inhibitor approved internationally for differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma — though it currently holds no market authorization in India. The TxGNN model predicts it may be effective for Liposarcoma (adipocytic sarcoma), with 1 completed Phase Ib/II clinical trial and 4 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Differentiated thyroid cancer, HCC, RCC, endometrial carcinoma (international approvals; no India license recorded) |
| Predicted New Indication | Liposarcoma (advanced adipocytic sarcoma) |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Lenvatinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that suppresses VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT. This broad anti-angiogenic and anti-proliferative profile has been validated across multiple solid tumour types characterised by VEGF/FGF pathway activation.
Liposarcoma — particularly the well-differentiated (WDLPS) and dedifferentiated (DDLPS) subtypes — is driven by CDK4 amplification and exhibits a highly vascularised tumour microenvironment. FGFR and PDGFRα signalling contribute to adipocytic tumour growth and immune evasion, placing lenvatinib’s multi-target profile in direct functional alignment. Notably, combining lenvatinib with eribulin (a microtubule inhibitor independently approved for liposarcoma) creates a complementary mechanism: lenvatinib disrupts tumour vasculature and suppresses VEGF-mediated immune escape, while eribulin induces mitotic arrest in tumour cells.
The LEADER study (NCT03526679) directly tested this rationale in advanced adipocytic sarcoma and leiomyosarcoma. Its completed Phase Ib/II results (PMID 36129471) and the biomarker evidence around CDK4 co-inhibition (PMID 39103896) further corroborate the mechanistic hypothesis generated by TxGNN’s knowledge-graph prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03526679 | Phase Ib/II | Completed | 30 | LEADER Study: lenvatinib 20 mg + eribulin in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma; safety and efficacy established; primary results published (PMID 36129471) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36129471 | 2022 | Phase Ib/II single-arm trial | Clinical Cancer Research | LEADER study primary publication: lenvatinib + eribulin in advanced liposarcoma and leiomyosarcoma; established safety profile and preliminary antitumour efficacy for the combination |
| 39103896 | 2024 | Translational / Biomarker cohort | Experimental Hematology & Oncology | CDK4 as a prognostic biomarker in soft tissue sarcoma; demonstrates synergistic potential of CDK4 inhibition in dedifferentiated liposarcoma sequential treatment, supporting combination strategies |
| 29848686 | 2018 | Preclinical combination study | Anticancer Research | Broad-spectrum preclinical antitumour activity of eribulin in combination with mechanistically different anticancer agents including antiangiogenics; supports the lenvatinib + eribulin rationale |
| 34326745 | 2021 | Case report | Case Reports in Oncology | Dedifferentiated liposarcoma lung metastasis treated with a comprehensive approach of targeted therapy, surgery, and chemotherapy; illustrates real-world challenges and multimodal strategies |
India Market Information
No product authorizations for Lenvatinib are currently registered in India. Lenvatinib holds regulatory approvals in the United States (FDA), European Union (EMA), Japan (PMDA), and other jurisdictions under the brand name Lenvima® for thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma.
Cytotoxicity
Lenvatinib is an antineoplastic agent (targeted therapy / multi-kinase inhibitor) approved across multiple oncology indications.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — multi-targeted receptor tyrosine kinase inhibitor (VEGFR/FGFR/PDGFRα/RET/KIT) |
| Myelosuppression Risk | Low to Moderate (less myelosuppression than conventional cytotoxics; thrombocytopenia and neutropenia have been reported, particularly in combination regimens) |
| Emetogenicity Classification | Low to Moderate |
| Monitoring Items | CBC (with differential), liver function tests (ALT/AST/bilirubin), renal function (creatinine/eGFR), blood pressure (hypertension is a frequent class effect), thyroid function (TSH), urinalysis (proteinuria), ECG if QT-prolonging agents co-administered |
| Handling Protection | Follow cytotoxic drug handling regulations; oral formulation — avoid crushing tablets; standard cytotoxic precautions apply during preparation and administration |
Safety Considerations
Specific warnings and contraindications from the India package insert are not available in this evidence pack (Data Gap DG001). Please refer to the Lenvima® prescribing information for complete safety data.
Key Drug Interactions (260 interactions identified in total; selected clinically significant interactions listed):
| Interacting Drug | Severity | Clinical Relevance |
|---|---|---|
| Dolasetron | Major | QT prolongation risk; avoid combination or monitor ECG closely |
| Cisapride | Major | QT prolongation risk; combination generally contraindicated |
| Clarithromycin | Moderate | CYP3A4 inhibition may increase lenvatinib exposure; monitor for toxicity |
| Levofloxacin | Moderate | Additive QT prolongation risk |
| Granisetron | Moderate | QT prolongation risk; use with caution |
| Palonosetron | Moderate | QT prolongation risk |
| Famotidine | Moderate | Potential pH-mediated effect on lenvatinib absorption |
| Naltrexone | Moderate | Pharmacodynamic interaction; clinical significance uncertain |
| Metronidazole | Minor | Low-level interaction; routine monitoring sufficient |
Note: The 260 total interactions highlight the need for a comprehensive medication reconciliation before initiating lenvatinib, especially in oncology patients receiving supportive care agents (antiemetics, laxatives, antibiotics).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The LEADER Phase Ib/II trial (NCT03526679, n=30) directly evaluated lenvatinib + eribulin in advanced liposarcoma and has been completed with published results (PMID 36129471), providing L2-level evidence. The mechanistic rationale is sound (VEGFR/FGFR/PDGFRα inhibition in a vascularised tumour context), and the combination leverages two agents with complementary mechanisms. However, the small trial size, single-arm design, and absence of India market authorisation require careful governance before clinical application.
To proceed, the following is needed:
- Regulatory pathway clarification: Lenvatinib is not approved in India; an import/compassionate use or clinical trial regulatory pathway must be established with CDSCO
- Full package insert review: Obtain and analyse Lenvima® prescribing information for complete contraindications, warnings, and special population data (DG001 remediation)
- MOA documentation: Retrieve full mechanism of action data from DrugBank DB09078 (DG002 remediation) to strengthen mechanistic rationale section
- Combination partner availability: Confirm eribulin (Halaven®) registration status in India, as the key evidence base is for the lenvatinib + eribulin combination
- Expanded evidence search: Consider a broader search for ongoing Phase II/III studies in dedifferentiated liposarcoma specifically, as the LEADER trial enrolled mixed sarcoma histotypes
- Pharmacovigilance plan: Given 260 documented DDIs and the lack of local post-marketing data, a structured risk management and monitoring protocol is required prior to any clinical use
- Biomarker strategy: Evaluate CDK4 amplification status and tumour vascularity profiling as potential patient selection criteria, based on PMID 39103896 findings
This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.